--- title: "Biovie | 10-Q: FY2026 Q3 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285996854.md" datetime: "2026-05-11T21:01:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285996854.md) - [en](https://longbridge.com/en/news/285996854.md) - [zh-HK](https://longbridge.com/zh-HK/news/285996854.md) generator: "portal-rs" --- # Biovie | 10-Q: FY2026 Q3 Revenue: USD 0 Revenue: As of FY2026 Q3, the actual value is USD 0. EPS: As of FY2026 Q3, the actual value is USD -0.7. EBIT: As of FY2026 Q3, the actual value is USD -5.5 M. BioVie Inc. operates as one operating segment, focusing on drug therapies for neurological and neurodegenerative disorders and advanced liver disease, with segment performance evaluated based on net loss and resource allocation managed by the CEO across functions, clinical trials, and development projects in line with company-wide strategic goals. #### Operational Metrics - **Net Loss** - For the three months ended March 31, 2026, net loss was approximately - $5.3 million, compared to approximately - $2.8 million for the three months ended March 31, 2025. - For the nine months ended March 31, 2026, net loss was approximately - $16.4 million, compared to approximately - $14.1 million for the nine months ended March 31, 2025. - **Total Operating Expenses** - For the three months ended March 31, 2026, total operating expenses were approximately $5.4 million, compared to $3.0 million for the three months ended March 31, 2025. - For the nine months ended March 31, 2026, total operating expenses were approximately $16.9 million, compared to $14.4 million for the nine months ended March 31, 2025. - **Research and Development (R&D) Expenses** - For the three months ended March 31, 2026, R&D expenses were approximately $3.2 million, compared to $1.3 million for the three months ended March 31, 2025. The net increase of approximately $1.9 million was mainly due to increased activities in the Sunrise PD Phase 2 study (up approximately $1.1 million) and the Long COVID (LC) Phase 2 study (up approximately $677,000). - For the nine months ended March 31, 2026, R&D expenses were approximately $10.4 million, an increase of approximately $2.4 million from $8.0 million for the nine months ended March 31, 2025. This increase included $2.5 million in direct study costs, $282,000 in clinical team compensation, and $176,000 for abstracts, publications, and conferences, partially offset by a $619,000 reduction in Chemistry, Manufacturing and Controls (CMC) and Discovery expenses. - **R&D Expenses by Study Program (Nine Months Ended March 31, 2026 vs. 2025)**: - Sunrise PD Phase 2: $6,055,000 (2026) vs. $2,648,000 (2025) - Liver Program Phase 3: $16,000 (2026) vs. $138,000 (2025) - Long COVID Phase 2: $4,625,000 (2026) vs. $4,233,000 (2025) - Long COVID Phase 2 - reimbursements: - $4,098,000 (2026) vs. - $2,920,000 (2025) - **General and Administrative Expenses** - For the three months ended March 31, 2026, general and administrative expenses were approximately $2.2 million, compared to $1.6 million for the three months ended March 31, 2025. The increase of approximately $565,000 was primarily due to increases in executive team and directors compensation (approximately $313,000 and $401,000, respectively, largely stock-based), increased insurance premiums (approximately $20,000), and accounting and auditing fees (approximately $16,000), partially offset by decreases in legal fees (approximately $123,000), other professional and consultancy fees (approximately $38,000), and investor and public relation expenses (approximately $24,000). - For the nine months ended March 31, 2026, general and administrative expenses were approximately $6.4 million, compared to $6.2 million for the nine months ended March 31, 2025. The increase of approximately $189,000 was primarily due to increases in executive team and directors compensation (approximately $78,000 and $214,000, respectively), legal expenses (approximately $423,000), investor and public relations expenses ($71,000), and insurance premiums (approximately $55,000), offset by decreases in consultancy fees (approximately $603,000), meetings and travel ($24,000), and accounting and auditing fees (approximately $14,000). - **Other Income and Expense** - For the three months ended March 31, 2026, other income, net was approximately - $115,000, compared to - $200,000 for the three months ended March 31, 2025. - For the nine months ended March 31, 2026, other income, net was approximately $505,000, compared to $350,000 for the nine months ended March 31, 2025. The net increase of approximately $155,000 was due to a $314,000 reduction in interest expense, offset by a $155,000 decline in interest income. #### Cash Flow - For the nine months ended March 31, 2026, net cash used in operating activities totaled approximately - $14.9 million. - Net cash provided by financing activities was approximately $10.5 million for the nine months ended March 31, 2026. #### Liquidity - As of March 31, 2026, BioVie Inc. had working capital of approximately $15.2 million, cash and cash equivalents of approximately $13.1 million, stockholders’ equity of approximately $15.6 million, and an accumulated deficit of approximately - $368.6 million. #### Future Outlook and Strategy BioVie Inc. expects to report topline results from its Phase 2b clinical trial for Parkinson’s Disease in mid-year 2026, though the timing is subject to change. The company’s future operations depend on the success of its ongoing development and commercialization efforts and its ability to secure additional financing, with management anticipating future funding from equity sales, loans, or other strategic transactions. These circumstances raise substantial doubt about BioVie Inc.’s ability to continue as a going concern. ### Related Stocks - [BIVI.US](https://longbridge.com/en/quote/BIVI.US.md) ## Related News & Research - [Home Depot announces R$ 0.29-per-unit dividend for Q3 2026](https://longbridge.com/en/news/296645065.md) - [Home Depot declares quarterly dividend of $2.33 a share](https://longbridge.com/en/news/296531433.md) - [Carlyle Credit Income Fund Q3 FY26 net investment income falls to $0.07 a share](https://longbridge.com/en/news/296394397.md) - [Havsfrun H1 FY26 net profit drops 72.58% to SEK 1.7 million](https://longbridge.com/en/news/296370588.md) - [Toll Brothers (TOL) Fiscal Q3 2026 Earnings Call: Margin, Orders and Guidance](https://longbridge.com/en/news/296394486.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**